

# KX2-391 (dihydrochloride)

Catalog No: tcsc0455



## Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg

Size: 100mg



## Specifications

**CAS No:**

1038395-65-1

**Formula:**

$C_{26}H_{31}Cl_2N_3O_3$

**Pathway:**

Protein Tyrosine Kinase/RTK;Cell Cycle/DNA Damage;Cytoskeleton

**Target:**

Src;Microtubule/Tubulin;Microtubule/Tubulin

**Purity / Grade:**

>98%

**Solubility:**

10 mM in DMSO

**Observed Molecular Weight:**

504.45

## Product Description


KX2-391 (dihydrochloride) is an inhibitor of **Src** that targets the peptide substrate site of Src, with **GI<sub>50</sub>** of 9-60 nM in cancer cell

lines.

IC50 & Target: GI50: 9 nM (Src HuH7), 13 nM (Src PLC/PRF/5), 26 nM (Src Hep3B), 60 nM (Src HepG2)

**In Vitro:** KX2-391 is a Src inhibitor that is directed to the Src substrate pocket. KX2-391 shows steep dose-response curves against Huh7 ( $GI_{50}$ =9 nM), PLC/PRF/5 ( $GI_{50}$ =13 nM), Hep3B ( $GI_{50}$ =26 nM), and HepG2 ( $GI_{50}$ =60 nM), four hepatic cell cancer (HCC) cell lines [1]. KX2-391 is found to inhibit certain leukemia cells that are resistant to current commercially available drugs, such as those derived from chronic leukemia cells with the T3151 mutation. KX2-391 is evaluated in engineered Src driven cell growth assays in NIH3T3/c-Src527F and SYF/c-Src527F cells and exhibits  $GI_{50}$  with 23 nM and 39 nM, respectively [2].

**In Vivo:** Orally administered KX2-391 is shown to inhibit primary tumor growth and to suppress metastasis, in pre-clinical animal models of cancer [2].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!